Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.08% is 60% below its 5-year average of 15.09%, near the low end of its 5-year range (6.08%–24.53%).
As of the fiscal period ended Wednesday, December 31, 2025. 13.76% below its 12-month average of 7.05%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
6.08%
RETURN ON EQUITY (ROE) AVG TTM
7.05%
RETURN ON EQUITY (ROE) AVG 3Y
11.93%
RETURN ON EQUITY (ROE) AVG 5Y
15.09%
RETURN ON EQUITY (ROE) AVG 10Y
15.68%
RETURN ON EQUITY (ROE) AVG 15Y
15.31%
RETURN ON EQUITY (ROE) AVG 20Y
15.55%
CURRENT VS TTM AVG
-13.76%
CURRENT VS 3Y AVG
-49.06%
CURRENT VS 5Y AVG
-59.70%
CURRENT VS 10Y AVG
-61.23%
CURRENT VS 15Y AVG
-60.28%
CURRENT VS 20Y AVG
-60.90%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-44.17%
vs the sector median at left
Humana Inc.
Market Cap
$45.76B
Return on Equity (ROE)
6.08%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$43.87B
Return on Equity (ROE)
70.38%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$47.81B
Return on Equity (ROE)
10.58%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$38.94B
Return on Equity (ROE)
19.85%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$53.72B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$37.17B
Return on Equity (ROE)
53.68%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$35.59B
Return on Equity (ROE)
22.26%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$57.58B
Return on Equity (ROE)
4.72%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$33.57B
Return on Equity (ROE)
8.55%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humana Inc. (HUM) | $45.76B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.87B | 70.38% | 60.82% | 72.53% | 81.69% |
| Edwards Lifesciences Corporation (EW)vs › | $47.81B | 10.58% | 26.07% | 24.86% | 23.86% |
| Agilent Technologies, Inc. (A)vs › | $38.94B | 19.85% | 20.59% | 21.51% | 20.54% |
| Cardinal Health, Inc. (CAH)vs › | $53.72B | -56.13% | -41.33% | 9.62% | -22.30% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $37.17B | 53.68% | -187.43% | 134.89% | 51.69% |
| IQVIA Holdings Inc. (IQV)vs › | $35.59B | 22.26% | 21.77% | 21.17% | 17.55% |
| Becton, Dickinson and Company (BDX)vs › | $57.58B | 4.72% | 6.60% | 6.50% | 6.42% |
| Medline Inc. (MDLN)vs › | $33.57B | 8.55% | 9.02% | 4.86% | 4.86% |
| Zoetis Inc. (ZTS)vs › | $32.24B | 81.75% | 66.19% | 56.82% | 52.60% |
ROE
6.1%
ROA
2.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 6.73% |
| 2024-12-31 | 7.37% |
| 2023-12-31 | 15.31% |
| 2022-12-31 | 18.33% |
| 2021-12-31 | 18.24% |
| 2020-12-31 | 24.53% |
| 2019-12-31 | 22.49% |
| 2018-12-31 | 16.56% |
| 2017-12-31 | 24.87% |
| 2016-12-31 | 5.75% |
| 2015-12-31 | 12.33% |
| 2014-12-31 | 11.89% |
| 2013-12-31 | 13.21% |
| 2012-12-31 | 13.81% |
| 2011-12-31 | 17.60% |
| 2010-12-31 | 15.87% |
| 2009-12-31 | 18.00% |
| 2008-12-31 | 14.52% |
| 2007-12-31 | 20.69% |
| 2006-12-31 | 15.96% |
| 2005-12-31 | 12.47% |
| 2004-12-31 | 13.40% |
| 2003-12-31 | 12.19% |
| 2002-12-31 | 8.89% |
| 2001-12-31 | 7.77% |
| 2000-12-31 | 6.62% |
| 1999-12-31 | -30.16% |
| 1998-12-31 | 7.64% |
| 1997-12-31 | 11.53% |
| 1996-12-31 | 0.93% |
